The CD19/CD20 CAR/TRuC-T cell therapy is positioned to address a significant unmet need in the treatment of relapsed/refractory B-cell lymphoma, a market characterized by high demand for innovative therapies. The trial, sponsored by Shenzhen University General Hospital, aims to evaluate both the safety and efficacy of this dual-targeting approach, which may enhance therapeutic outcomes compared to existing CAR-T therapies. Given the increasing prevalence of B-cell malignancies and the limitations of current treatments, successful trial results could lead to a competitive advantage in a rapidly evolving market. The asset's development aligns with the growing trend towards personalized medicine and advanced cell therapies, potentially attracting interest from strategic partners and investors.